Revision as of 21:34, 30 April 2017 editBiochemistry&Love (talk | contribs)Extended confirmed users, New page reviewers5,950 edits →Unsourced: Changed indicated->labeled, since "indication" is a decision made, not a label. Cited a PL chart.← Previous edit | Revision as of 02:56, 18 October 2017 edit undoBiochemistry&Love (talk | contribs)Extended confirmed users, New page reviewers5,950 edits Added some pubchem refs.Next edit → | ||
Line 24: | Line 24: | ||
*]<ref name="PharmLetter BB Table">{{cite web|title=Comparison of Oral Beta-Blockers|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Dec/Comparison-of-Oral-Beta-Blockers-5052|website=pharmacist.therapeuticresearch.com|publisher=Therapeutic Research Center|accessdate=30 April 2017}}</ref> | *]<ref name="PharmLetter BB Table">{{cite web|title=Comparison of Oral Beta-Blockers|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Dec/Comparison-of-Oral-Beta-Blockers-5052|website=pharmacist.therapeuticresearch.com|publisher=Therapeutic Research Center|accessdate=30 April 2017}}</ref> | ||
*] (has additional α1-blocking activity)<ref>{{cite journal |vauthors=Rosendorff C |title=Beta-blocking agents with vasodilator activity |journal=Journal of Hypertension. Supplement |volume=11 |issue=4 |pages=S37–40 |year=1993 |pmid=8104240 |doi=10.1097/00004872-199306003-00009}}</ref> | *] (has additional α1-blocking activity)<ref>{{cite journal |vauthors=Rosendorff C |title=Beta-blocking agents with vasodilator activity |journal=Journal of Hypertension. Supplement |volume=11 |issue=4 |pages=S37–40 |year=1993 |pmid=8104240 |doi=10.1097/00004872-199306003-00009}}</ref> | ||
*]<ref>{{cite web|title=CARTEOLOL|url=https://pubchem.ncbi.nlm.nih.gov/compound/carteolol|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> | |||
*] | |||
*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> | *] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> | ||
*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> | *] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" /> | ||
*]<ref name="PharmLetter BB Table" /> | *]<ref name="PharmLetter BB Table" /> | ||
*] (has intrinsic sympathomimetic activity)<ref>{{cite web|title=oxprenolol|url=https://pubchem.ncbi.nlm.nih.gov/compound/4631|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> | |||
*] | |||
*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> | *] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> | ||
*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> | *] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" /> | ||
Line 40: | Line 40: | ||
*]<ref name="PharmLetter BB Table" /> | *]<ref name="PharmLetter BB Table" /> | ||
*]<ref name="PharmLetter BB Table" /> | *]<ref name="PharmLetter BB Table" /> | ||
*] (has intrinsic sympathomimetic activity)<ref>{{cite web|title=Celiprolol|url=https://pubchem.ncbi.nlm.nih.gov/compound/2663|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> | |||
*] | |||
*]<ref name="PharmLetter BB Table" /> | *]<ref name="PharmLetter BB Table" /> | ||
*]<ref name="PharmLetter BB Table" /> | *]<ref name="PharmLetter BB Table" /> | ||
;β<sub>2</sub>-selective agents | ;β<sub>2</sub>-selective agents | ||
*]<ref>{{cite web|title=Butaxamine|url=https://pubchem.ncbi.nlm.nih.gov/compound/18026|website=pubchem.ncbi.nlm.nih.gov|publisher=U.S. National Library of Medicine|accessdate=18 October 2017|language=en}}</ref> | |||
*] | |||
*] | *] | ||
Revision as of 02:56, 18 October 2017
Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Beta blocker.
|
This is the talk page for discussing improvements to the Beta blocker article. This is not a forum for general discussion of the article's subject. |
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Archives: 1Auto-archiving period: 2 months |
Pharmacology C‑class Top‑importance | ||||||||||
|
Unsourced
Moved here per WP:PRESERVE as this is almost all unsourced. Per WP:BURDEN please do not restore without finding reliable sources, checking the content against them, and citing the sources.
- Examples
- Nonselective agents
- Propranolol
- Bucindolol (has additional α1-blocking activity)
- Carteolol
- Carvedilol (has additional α1-blocking activity)
- Labetalol (has additional α1-blocking activity)
- Nadolol
- Oxprenolol (has intrinsic sympathomimetic activity)
- Penbutolol (has intrinsic sympathomimetic activity)
- Pindolol (has intrinsic sympathomimetic activity)
- Sotalol (not considered a "typical beta-blocker")
- Timolol
- β1-selective agents
Also known as cardioselective
- Acebutolol (has intrinsic sympathomimetic activity, ISA)
- Atenolol
- Betaxolol
- Bisoprolol
- Celiprolol (has intrinsic sympathomimetic activity)
- Metoprolol
- Nebivolol
- β2-selective agents
- β3-selective agents
- Comparative information
- Pharmacological differences
- Agents with intrinsic sympathomimetic action (ISA)
- Acebutolol, carteolol, celiprolol, mepindolol, oxprenolol, pindolol
- Agents with greater aqueous solubility (hydrophilic beta blockers)
- Atenolol, celiprolol, nadolol, sotalol
- Agents with membrane stabilizing effect
- Acebutolol, propranolol
- Indication differences
- Agents specifically labeled for cardiac arrhythmia
- Agents specifically labeled for congestive heart failure
- Agents specifically labeled for glaucoma
- Agents specifically labeled for myocardial infarction
- Agents specifically labeled for migraine prophylaxis
Propranolol is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma.
References
- ^ "Comparison of Oral Beta-Blockers". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
- Rosendorff C (1993). "Beta-blocking agents with vasodilator activity". Journal of Hypertension. Supplement. 11 (4): S37–40. doi:10.1097/00004872-199306003-00009. PMID 8104240.
- "CARTEOLOL". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- "oxprenolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- "Celiprolol". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- "Butaxamine". pubchem.ncbi.nlm.nih.gov. U.S. National Library of Medicine. Retrieved 18 October 2017.
- "Drugs to Prevent Migraine in Adults". pharmacist.therapeuticresearch.com. Therapeutic Research Center. Retrieved 30 April 2017.
- Cite error: The named reference
Rossi
was invoked but never defined (see the help page).